Replies to post #6680 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Kccole, I agree that investor are probably taking a wait and see approach. but how many Small Caps sit on their hands and avoid investor conferences for 14+ months and withhold potentially price moving info?

ANIP keeps many of its assets close to the vest and intentionally doesn't advertise all its assets or connections. Such as the stake it has in Cold Genesys, it use to be 19.9 % (probably closer to 15% by now) plus future royalties. Yet Pryzbyl sits on the BOD for Cold Genesys.


Cold Genesys BOD

It is true that Libigel doesn't get much attention probably because ANIP never mentions it. They have never advertised that it reduced cardiovascular events by at least 70% or that it reduces Breast Cancer events (only discovered in late 2015). Now ask yourself why keep this quiet? It would certainly draw in investors. It doesn't make sense unless they are contractually restricted from discussing it. To Top it off now, even Investor Relations is no longer at liberty to provide updates on Libigel.

There is much more to this company than meets the eye. Hopefully soon enough this will become evident.